ProPhase Labs, Inc. (PRPH) intrinsic value & 10-year financials
ProPhase Labs, Inc. (PRPH) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue shrank 16.1% a year to $4.3M, with an average return on invested capital of -36.6%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.01
- Market cap
- $77.2K
- Revenue (FY2025)
- $4.3M
- Revenue growth (10-yr CAGR)
- -16.1%
- ROIC (10-yr avg)
- -36.6%
- Free cash flow (FY2025)
- -$8.3M
PRPH 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $4.3M | -$14.7M | -$1.74 | -$8.3M | -415.4% | -177.9% |
| FY2024 | $6.8M | -$53.4M | -$2.61 | -$18.4M | -570.6% | -102.7% |
| FY2023 | $44.4M | -$16.8M | -$0.98 | -$14.5M | -48.7% | -27.0% |
| FY2022 | $122.6M | $18.5M | $1.02 | $24.6M | 19.2% | 33.6% |
| FY2021 | $79.0M | $6.3M | $0.40 | -$17.9M | 12.4% | 31.3% |
| FY2020 | $14.5M | -$2.1M | -$0.18 | $903.0K | -14.4% | -25.7% |
| FY2019 | $9.9M | -$3.1M | — | -$1.1M | -32.8% | -22.7% |
| FY2018 | $13.1M | -$1.7M | -$0.15 | -$2.3M | -12.4% | -6.6% |
| FY2017 | $9.9M | $41.8M | $0.00 | -$3.0M | -40.4% | -20.4% |
| FY2016 | $21.0M | -$2.9M | -$0.00 | -$1.1M | -12.6% | -48.1% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
ProPhase Labs, Inc. is facing top-line stagnation, with revenue contracting over the decade.
ProPhase Labs, Inc. has historically struggled to out-earn its cost of capital, averaging just -19.0% ROIC.
Over the decade, ProPhase Labs, Inc. shows that management has aggressively returned capital to shareholders by retiring 31.5% of outstanding shares.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, ProPhase Labs, Inc. is modeled at -16.1% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-20.80 per share.